AI drug discovery company
METiS TechBio
Data as of .
Company facts
-
Founded
2020
-
Headquarters
China (Beijing and Hangzhou)
Latest funding round
- Round
- IPO (HKEX main board)
- Date
- May 13, 2026
- Amount
- HKD 2.113B (approx. $269.8M)
Drug discovery partners
0 pharma, 1 other. Pharma here means a company with approved products and roughly $1B or more in annual revenue.
-
Boulevard Bio Biotech
Asset license (MTS-128),
$20M upfront ($1.62B total potential)
Drugs on the board
- MTS-128
Preclinical per company
Autoimmune disease
Recent news
-
Hong Kong IPO raised over HKD 2.1B
-
Hong Kong IPO in May raised $269M
-
Asset license (MTS-128) with Boulevard Bio ($20M upfront ($1.62B total potential))
-
IPO (HKEX main board): HKD 2.113B (approx. $269.8M)
-
Debuts on the Hong Kong Stock Exchange main board
Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.
Spot an error? Tell me and I'll fix it.